Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.

Trial Profile

A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs EMD 640744 (Primary) ; Cyclophosphamide; Pembrolizumab
  • Indications Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors IMV
  • Most Recent Events

    • 08 Feb 2019 Status changed from planning to recruiting.
    • 02 Nov 2018 According to an IMV media release, preliminary data from this trial is expected in 2019.
    • 20 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top